Breaking News
Sort by:
Top Post
Almirall Appoints Mercedes Diz as VP, Corporate Strategy
Almirall, a global biopharmaceutical company focused on skin health, today announced that Mercedes Diz will […]
Concord Health Partners Adds Healthcare Private Equity Veteran Robert Schulz as Managing Director
Concord Health Partners (“Concord” or the “Firm”), a healthcare focused investment firm, today announced that […]
Wheeler Bio Announces Roger Lias, Ph.D. as President and Chief Operating Officer
Wheeler Bio, a new contract development and manufacturing organization (CDMO) specializing in the cell line […]
Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer
Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the […]
Precigen Names Rutul R. Shah Chief Operating Officer
Precigen, Inc. ( Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies […]
ViroCell Announces the Appointment of Susan B. Nichols as CBO
ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply […]
FUJIFILM Cellular Dynamics Announces the Appointment of Dr. Ilyas Singeç as Chief Scientific Officer
FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem […]
Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer
Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop […]
Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer
Biolojic Design, a pioneer in the use of artificial intelligence (AI) in antibody design, today announced […]
Prolifagen Therapeutics Appoints M. Alexander Shaw, PhD, as Chief Executive Officer
Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, […]
Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer
Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more